Cargando…
Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies
BACKGROUND/AIMS: To evaluate intravitreal aflibercept versus laser in subgroups of patients with baseline Diabetic Retinopathy Severity Scale (DRSS) scores ≤43, 47, and ≥53 in VIVID-DME and VISTA-DME. METHODS: Patients with diabetic macular oedema were randomised to receive intravitreal aflibercept...
Autores principales: | Staurenghi, Giovanni, Feltgen, Nicolas, Arnold, Jennifer J, Katz, Todd A, Metzig, Carola, Lu, Chengxing, Holz, Frank G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047149/ https://www.ncbi.nlm.nih.gov/pubmed/29051325 http://dx.doi.org/10.1136/bjophthalmol-2017-310664 |
Ejemplares similares
-
Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies
por: Midena, Edoardo, et al.
Publicado: (2018) -
Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data
por: Ziemssen, Focke, et al.
Publicado: (2016) -
Analysis of DME/DME Navigation Performance and Ground Network Using Stretched-Front-Leg Pulse-Based DME
por: Kim, Euiho
Publicado: (2018) -
The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers
por: Munk, Marion R., et al.
Publicado: (2022) -
Risk Factors for Retinopathy and DME in Type 2 Diabetes—Results from the German/Austrian DPV Database
por: Hammes, Hans-Peter, et al.
Publicado: (2015)